ArticleThe Journal of antimicrobial chemotherapy2015
Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae.
Article in The Journal of antimicrobial chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Triple combination antibiotic therapy for carbapenemase-producing Klebsiella pneumoniae: a systematic review.Annals of clinical microbiology and antimicrobials · 2017Pooled it
- Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae.Annals of clinical microbiology and antimicrobials · 2017Pooled it
- Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis.Medicine · 2016Pooled it
- Safety and immunogenicity of an adjuvantedHuman vaccines & immunotherapeutics · 2021Trial
- Multicenter Point-Prevalence Study of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Clinical Epidemiological Analysis of the Genotypic Spectrum and Mortality Risk in Carbapenem-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Exploring New Delhi Metallo Beta Lactamases in Klebsiella pneumoniae and Escherichia coli: genotypic vs. phenotypic insights.Annals of clinical microbiology and antimicrobials · 2025Article
- Heteroresistance associated with the production of fosfomycin-resistant inner colonies during disk diffusion testing among a geographically diverse collection ofJAC-antimicrobial resistance · 2025Article
- High prevalence of OXA-48-like and NDM carbapenemases among carbapenem resistantIranian journal of microbiology · 2023Article
- Aminoglycosides for the Treatment of Severe Infection Due to Resistant Gram-Negative Pathogens.Antibiotics (Basel, Switzerland) · 2023Review
- Elevated Mortality Risk from CRKp Associated with Comorbidities: Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2022Review
- Article
- Mortality-Related Risk Factors and Novel Antimicrobial Regimens for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review.Infection and drug resistance · 2022Review
- Prevalence of Carbapenem-ResistantInfection and drug resistance · 2022Article
- Role of tigecycline in the treatment of urinary tract infections: a systematic review of published case reports.Le infezioni in medicina · 2022Review
- Present and Future Perspectives on Therapeutic Options for Carbapenemase-ProducingMicroorganisms · 2021Review
- Detection ofDiseases (Basel, Switzerland) · 2021Article
- Does Antimicrobial Therapy Affect Mortality of Patients with Carbapenem-ResistantMicroorganisms · 2020Article
- The Pitt Bacteremia Score Predicts Mortality in Nonbacteremic Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Observational
- Extended-SpectrumInterdisciplinary perspectives on infectious diseases · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 1 country.
Funding
Abstract
objectivesCarbapenem-resistant Klebsiella pneumoniae (CRKP) is an important healthcare-associated pathogen. We evaluated the impact of CRKP strain type and treatment on outcomes of patients with CRKP bacteriuria. PATIENTS AND
methodsPhysician-diagnosed CRKP urinary tract infection (UTI)-defined as those patients who received directed treatment for CRKP bacteriuria-was studied in the multicentre, prospective Consortium on Resistance against Carbapenems in Klebsiella pneumoniae (CRaCKle) cohort. Strain typing by repetitive extragenic palindromic PCR (rep-PCR) was performed. Outcomes were classified as failure, indeterminate or success. Univariate and multivariate ordinal analyses to evaluate the associations between outcome, treatment and strain type were followed by binomial analyses.
resultsOne-hundred-and-fifty-seven patients with physician-diagnosed CRKP UTI were included. After adjustment for CDC/National Healthcare Safety Network (NHSN)-defined UTI, critical illness and receipt of more than one active antibiotic, patients treated with aminoglycosides were less likely to fail therapy [adjusted OR (aOR) for failure 0.34, 95% CI 0.15-0.73, P=0.0049]. In contrast, patients treated with tigecycline were more likely to fail therapy (aOR for failure 2.29, 95% CI 1.03-5.13, P=0.0425). Strain type data were analysed for 55 patients. The predominant clades were ST258A (n=18, 33%) and ST258B (n=26, 47%). After adjustment for CDC/NHSN-defined UTI and use of tigecycline and aminoglycosides, infection with strain type ST258A was associated with clinical outcome in ordinal analysis (P=0.0343). In multivariate binomial models, strain type ST258A was associated with clinical failure (aOR for failure 5.82, 95% CI 1.47-28.50, P=0.0113).
conclusionsIn this nested cohort study of physician-diagnosed CRKP UTI, both choice of treatment and CRKP strain type appeared to impact on clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.